Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

If you guessed weight loss, you are right on the money. Therapies in this field, such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy, are generating mouthwatering sales, so it's no wonder other ...

A new weight loss pill called amycretin has helped people lose up to 13% of their body weight in just three months, according ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...

This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

The compound was oral amycretin -- an amylin and GLP-1 receptor co-agonist -- said Agnes Gasiorek, PhD, MSc Pharm, of Novo Nordisk in Måløv, Denmark. It's the first long-acting compound to target both ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...